Bio-Rad to License Globavir Biosciences Dengue Detection Assay | GenomeWeb

NEW YORK (GenomeWeb) – Globavir Biosciences announced today that Bio-Rad Laboratories will license its PCR-based detection technology and assay for dengue virus detection.

Globavir's PanGlob assay improves diagnostic sensitivity and efficacy across four dengue serotypes, and it displays enhanced specificity for dengue over related viruses, the firm said. Globavir has obtained rights to develop and commercialize a dengue diagnostic test platform developed at Stanford University. Its diagnostic kits have received CE-mark approval.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.